The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands

Zacks
17 Mar

For Immediate Release

Chicago, IL – March 17, 2025 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Lockheed Martin Corp. LMT, Dell Technologies Inc. DELL and Hamilton Beach Brands Holding Co. HBB.

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for AbbVie, Lockheed Martin and Dell

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc., Lockheed Martin Corp. and Dell Technologies Inc., as well as a micro-cap stock Hamilton Beach Brands Holding Co. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Pre-Market Futures in the Green... for Now

Today's Featured Research Reports

AbbVie’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+20.1% vs. +5.3%). The company has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and should support top-line growth in the next few years.

AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. It expects to return to robust revenue growth in 2025 following the Humira LOE. AbbVie has been on an acquisition spree lately in its core space of immunology.

However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth trend for Juvederm fillers in the United States and China.

(You can read the full research report on AbbVie here >>>)

Shares of Lockheed Martin have outperformed the Zacks Aerospace - Defense industry over the past year (+9.6% vs. -4.5%). The company remains the largest U.S. defense contractor with a steady order flow from its leveraged presence in the Army, Air Force, Navy and IT programs. The company’s products are also well-acclaimed in the international market.

The increased funding offered for its defense products by the U.S. government should boost its business. The F-35 combat jet program remains a major revenue contributor for Lockheed. The company holds a strong solvency position.

However, Lockheed is facing performance issues concerning some of its programs that may lead to notable losses. A shortage of skilled labor in the aerospace and defense industry may adversely impact Lockheed’s future operating results. The sanctions imposed by China on Lockheed might also affect its business.

(You can read the full research report on Lockheed Martin here >>>)

Dell’s shares have underperformed the Zacks Computer - Micro Computers industry over the past year (-9.7% vs. +20.8%). The company is suffering from a challenging macroeconomic environment. It suffers from stiff competition in the PC market from the likes of HP and Lenovo.

Nevertheless, Dell is benefiting from strong demand for AI servers driven by ongoing digital transformation and heightened interest in generative AI applications. Its PowerEdge XE9680L AI-optimized server is very much in demand. Strong enterprise demand for AI-optimized servers is aiding Dell. It is witnessing demand from a diversified customer base that includes the likes of higher education institutions, financial services, health care and life services and manufacturing.

An expanding partner base that includes the likes of NVIDIA, Microsoft, Meta Platforms and Imbue has been a major growth driver. Dell’s shareholder-friendly approach makes it an attractive investment.

(You can read the full research report on Dell here >>>)

Shares of Hamilton Beach have declined -7.2% over the past year against the Zacks Household Appliances industry’s decline of -8.3%. This microcap company with market capitalization of $268.27 million achieved a record gross margin of 26% in 2024, up 300 bps year over year, driven by lower costs, improved mix and pricing discipline. Operating profit rose 23.1% to $43.2 million.

A strong cash flow of $65.4 million enabled debt elimination, ending with a net cash position of $0.6 million. HBB expanded into high-margin healthcare with HealthBeacon, targeting more than 50% patient growth in 2025. Product innovation, including premium offerings and e-commerce expansion, is driving market share gains. U.S. consumer sales rose 3.6%, with strong growth in Mexico and commercial blender placements.

Proactive tariff mitigation and supply-chain diversification protect margins. The 2025 guidance includes mid-single-digit revenue growth, operating profit outpacing sales and $40-$50 million in free cash flow.

(You can read the full research report on Hamilton Beach here >>>)

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Lockheed Martin Corporation (LMT) : Free Stock Analysis Report

Dell Technologies Inc. (DELL) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

Hamilton Beach Brands Holding Company (HBB) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10